Uses and isolation of very small of embryonic-like (vsel) stem cells
OwnerMariusz Ratajczak, Magdalena Kucia +6inventors
InventorsMariusz Ratajczak, Magdalena Kucia, Janina Ratajczak, Denis O. Rodgerson, George S. Smith, Roberto Bolli, Ronald E. Allen, Wayne A. Marasco
Life of this patent
Estimating the term…
Abstract
The presently disclosed subject matter provides populations of stem cells that are purified from bone marrow, peripheral blood, and/or other sources. Also provided are methods of using the stem cells for treating tissue and/or organ damage in a subject.
Claims38
A method of collecting autologous VSELs from a subject comprising the steps of:
- administering to the subject a stem cell potentiating agent;
- collecting at least 1010 total nucleated cells from the peripheral blood of the subject;
- enriching the total nucleated cells for CD34+/lin−/CD45− or Sca-1+/lin−/CD45− very small embryonic-like stem cells (VSELs);
- and
- preserving the collected cells to maintain the cellular integrity of the cells.
A cellular therapy product comprising an autologous mixture of Sca-1+/Lin−/CD45− very small embryonic-like stem cells (VSELs) and non-VSELs, wherein the non-VSELs comprise progenitor cells and optionally functional cells.
A method of enhancing the engraftment of stem cells comprising administering to a subject an autologous mixture of CD34+/lin−/CD45− or Sca-1+/lin−/CD45− very small embryonic-like stem cells (VSELs), progenitor cells, and optionally functional cells.
A cellular therapy product comprising at least 104 CD34+/Iin−/CD45− or Sca-1+/lin−/CD45− very small embryonic-like stem cells (VSELs).
A process of making stem cells and progenitor cells available to a person, comprising the steps of:
- the person proactively electing to have his CD34+/lin−/CD45− or Sca-1+/lin−/CD45− very small embryonic-like stem cells (VSELs) collected, wherein the person has no immediate perceived health condition requiring immediate treatment using his own collected stem cells and progenitor cells;
- collecting at least 1010 total nucleated cells from the peripheral blood of the person using an apheresis process;
- at the time of collection, earmarking the collected cells for use by the person;
- and preserving the collected cells in storage.
A process for collecting and banking CD34+/lin−/CD45− or Sca-1+/lin−/CD45− very small embryonic-like stem cells (VSELs) of a person, comprising the steps of collecting at least 1010 total nucleated cells from peripheral blood of a person with no immediate perceived health condition requiring immediate treatment using an apheresis process;
- at the time of collection, earmarking the collected VSELs for use by the person;
- and preserving the collected cells by storage in a cell bank.
A method of treating an injury to a tissue in a subject, the method comprising administering to the subject a composition comprising CD34+/lin−/CD45− or Sca-1+/lin−/CD45− very small embryonic-like stem cells (VSELs) in a pharmaceutically acceptable carrier, in an amount and via a route sufficient to allow at least a fraction of the population of VSELs to engraft the tissue and differentiate therein, wherein the injury is selected from the group consisting of an ischemic injury, a myocardial infarction, and stroke.
Dependencies are inferred from the claim text.